Response to prime editing study
Lucy Allen, Director of Research and Healthcare Data at Cystic Fibrosis Trust said: “Prime editing is genetic therapy technique being developed that could one day be used to treat people with cystic fibrosis (CF), a life-long and life-limiting condition without a cure. It’s encouraging to see the positive results in these studies correcting the most common CF gene mutation, F508Del, and we hope future research could lead to the development of genetic therapy treatments for those with rarer CF mutations too. A crucial step will be getting these potential treatments delivered to where they need to be in the body, and we hope further advances in these technologies could make long-term treatment for everyone with CF a possibility.”